NAD+ Injection & IV Pricing: April 2026

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy production, DNA repair, and sirtuin activation. NAD+ levels decline ~50% between ages 40 and 60, driving widespread interest in supplementation for longevity, cellular energy, cognitive performance, and addiction recovery. Though not technically a peptide, NAD+ is grouped with peptide therapy because it's typically delivered via injection or IV compounding channels.

Critical bioavailability point: Oral NAD+ is functionally useless — NAD+ degrades in the GI tract. Clinical effects require injection (IV, subcutaneous, or IM) or nasal spray. The legitimate oral options are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — NAD+ precursors that are well-absorbed orally (e.g., 1,000 mg NR produces a 142% NAD+ increase).

Available forms:

• IV infusion (250–1,000 mg per session; 90 min to 5+ hours; highest bioavailability)
• Subcutaneous injection (20–100 mg per dose, 1–3x weekly; self-administered at home)
• Intramuscular injection (less common; similar dose range)
• Nasal spray (compounded; convenient, moderate bioavailability)
• Transdermal patches (iontophoresis; ~400 mg delivered; AgelessRx)
• Oral NMN/NR precursors (legal supplement route — different molecules, same goal)

Typical protocols:

• Loading phase: 4–10 consecutive daily IV sessions (500–1,000 mg each). Addiction detox uses 10–14 days at up to 8 hours/day.
• Maintenance: Monthly IV, or weekly/bi-weekly subcutaneous injections.
• SC daily dosing: Start at 0.1 mL (20 mg), titrate up to 0.5 mL (100 mg) 1–3x/week.

Regulatory status: NAD+ is not FDA-approved as a finished drug. Injectable/IV/nasal spray forms are compounded by 503A/503B pharmacies (Empower, Olympia, etc.) from FDA-registered APIs under prescription. Oral NMN was reclassified by FDA as a drug (not a supplement) in 2022, creating a regulatory gray area; NR remains a legal supplement. Insurance does not cover NAD+ therapy.